Nabriva Therapeutics plc

  • TickerNBRV
  • ISINIE00BYQMW233
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryIreland

Analysts

ValuEngine Rating and Forecast Report for NBRV

ValuEngine Rating and Forecast Report for NBRV

Ashiq Mubarack ...
  • David Nierengarten
  • Robert Driscoll

Q1 Financials, Recent Setbacks Priced In at Current Levels

Ashiq Mubarack ...
  • David Nierengarten
  • Robert Driscoll

Q1 Financials, Recent Setbacks Priced In at Current Levels

2 directors bought

Two Directors at Nabriva Therapeutics plc bought 50,500 shares at 2.750USD. The significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. T...

ValuEngine Rating and Forecast Report for NBRV

ValuEngine Rating and Forecast Report for NBRV

ValuEngine Rating and Forecast Report for NBRV

ValuEngine Rating and Forecast Report for NBRV

ValuEngine Rating and Forecast Report for NBRV

ValuEngine Rating and Forecast Report for NBRV

ValuEngine Rating and Forecast Report for NBRV

ValuEngine Rating and Forecast Report for NBRV

ValuEngine Rating and Forecast Report for NBRV

ValuEngine Rating and Forecast Report for NBRV

ResearchPool Subscriptions

Get the most out of your insights

Get in touch